Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
| ▸ | TEK | Q02763 | 1/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 4/20 | 0.32 |
| ▸ | BRD7 | Q9NPI1 | 4/20 | 0.32 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | PDE5A | O76074 | 2/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | BRD2 | P25440 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15845724 | 0.91 | EGFR (0.33) | EGFRIGF1RSRCFLT4KDR | |
| SCHEMBL15845725 | 0.88 | DDR1 (0.33) | EGFRIGF1RSRCFLT4KDR | |
| SCHEMBL15845596 | 0.85 | EGFR (0.35) | EGFRIGF1RSRCFLT4KDR | |
| SCHEMBL15846106 | 0.84 | MAPK1 (0.35) | EGFRIGF1RSRCFLT4KDR | |
| SCHEMBL18393405 | 0.84 | DDR1 (0.35) | EGFRIGF1RSRCFLT4KDR | |
| SCHEMBL15845716 | 0.81 | HRH3 (0.33) | — | |
| SCHEMBL15846446 | 0.81 | DDR1 (0.33) | EGFRIGF1RSRCFLT4KDR | |
| SCHEMBL15846339 | 0.80 | TGFBR1 (0.35) | EGFRIGF1RSRCFLT4KDR | |
| SCHEMBL15846194 | 0.79 | NPC1 (0.30) | — | |
| SCHEMBL15845809 | 0.79 | EGFR (0.36) | EGFRIGF1RSRCFLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656971-B2 | COMT inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160002177-A1 | COMT INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002177-A1 | COMT INHIBITORS | COMT, PNMT, SLC6A3 | EGFR 4189/4885IGF1R 4261/4885SRC 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.